PIP3/AKT and ERK1/2 are the key signalling hubs, reported to play a crucial role in development of therapy resistance in multiple carcinoma including ovarian cancer [11,14,[30], [31], [32]]. This evidence concerns the gene AKT1 and ovarian cancer.